Frazier Life Sciences Management as of Dec. 31, 2023
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 49 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 10.3 | $192M | 6.5M | 29.52 | |
| Hillevax (HLVX) | 8.4 | $157M | 9.8M | 16.05 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 7.2 | $136M | 12M | 11.17 | |
| Krystal Biotech (KRYS) | 6.6 | $123M | 989k | 124.06 | |
| Bridgebio Pharma (BBIO) | 5.9 | $110M | 2.7M | 40.37 | |
| Rhythm Pharmaceuticals (RYTM) | 5.8 | $109M | 2.4M | 45.97 | |
| Phathom Pharmaceuticals (PHAT) | 4.9 | $92M | 10M | 9.13 | |
| Vaxcyte (PCVX) | 3.9 | $73M | 1.2M | 62.80 | |
| Verona Pharma Sponsored Ads (VRNA) | 3.2 | $60M | 3.0M | 19.88 | |
| Alpine Immune Sciences | 3.2 | $60M | 3.1M | 19.06 | |
| Apellis Pharmaceuticals (APLS) | 2.8 | $53M | 885k | 59.86 | |
| Rocket Pharmaceuticals (RCKT) | 2.4 | $46M | 1.5M | 29.97 | |
| Disc Medicine (IRON) | 2.4 | $45M | 785k | 57.76 | |
| Kalvista Pharmaceuticals (KALV) | 2.4 | $44M | 3.6M | 12.25 | |
| Tarsus Pharmaceuticals (TARS) | 1.9 | $36M | 1.8M | 20.25 | |
| Edgewise Therapeutics (EWTX) | 1.6 | $29M | 2.7M | 10.94 | |
| Revolution Medicines (RVMD) | 1.5 | $29M | 998k | 28.68 | |
| An2 Therapeutics (ANTX) | 1.5 | $29M | 1.4M | 20.49 | |
| Arcutis Biotherapeutics (ARQT) | 1.5 | $28M | 8.8M | 3.23 | |
| Aerovate Therapeutics (AVTE) | 1.5 | $27M | 1.2M | 22.63 | |
| Autolus Therapeutics Spon Ads (AUTL) | 1.3 | $24M | 3.7M | 6.44 | |
| Macrogenics (MGNX) | 1.2 | $23M | 2.4M | 9.62 | |
| ACADIA Pharmaceuticals (ACAD) | 1.2 | $23M | 731k | 31.31 | |
| 89bio (ETNB) | 1.2 | $22M | 2.0M | 11.17 | |
| Merus N V (MRUS) | 1.1 | $21M | 747k | 27.50 | |
| Oric Pharmaceuticals (ORIC) | 1.1 | $20M | 2.1M | 9.20 | |
| Anaptysbio Inc Common (ANAB) | 1.0 | $19M | 900k | 21.42 | |
| Savara (SVRA) | 1.0 | $19M | 4.0M | 4.70 | |
| Soleno Therapeutics (SLNO) | 1.0 | $19M | 465k | 40.25 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.9 | $17M | 393k | 42.40 | |
| Deciphera Pharmaceuticals | 0.9 | $17M | 1.0M | 16.13 | |
| Madrigal Pharmaceuticals (MDGL) | 0.9 | $16M | 69k | 231.38 | |
| Dyne Therapeutics (DYN) | 0.8 | $16M | 1.2M | 13.30 | |
| Silence Therapeutics Ads (SLN) | 0.8 | $15M | 881k | 17.37 | |
| Tyra Biosciences (TYRA) | 0.8 | $14M | 1.0M | 13.85 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $14M | 398k | 35.58 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 0.7 | $13M | 317k | 40.76 | |
| Arvinas Ord (ARVN) | 0.6 | $12M | 285k | 41.16 | |
| Cogent Biosciences (COGT) | 0.6 | $12M | 2.0M | 5.88 | |
| Agios Pharmaceuticals (AGIO) | 0.6 | $12M | 523k | 22.27 | |
| Apogee Therapeutics (APGE) | 0.6 | $11M | 400k | 27.94 | |
| Trevi Therapeutics (TRVI) | 0.5 | $9.9M | 7.4M | 1.34 | |
| Theseus Pharmaceuticals | 0.5 | $8.6M | 2.1M | 4.05 | |
| Intellia Therapeutics (NTLA) | 0.3 | $6.2M | 204k | 30.49 | |
| Mirati Therapeutics | 0.3 | $4.7M | 80k | 58.75 | |
| Bluebird Bio (BLUE) | 0.1 | $2.4M | 1.7M | 1.38 | |
| Gritstone Oncology Ord (GRTS) | 0.1 | $2.1M | 1.0M | 2.04 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $1.6M | 500k | 3.13 | |
| Aclaris Therapeutics (ACRS) | 0.0 | $278k | 264k | 1.05 |
